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doi:10.1016/j.hkjn.2011.09.007Summary Background: Conversion of standard-release tacrolimus to prolonged-release
once-daily tacrolimus is often performed in a 1:1 (mg:mg) manner. We sought to determine
the safety and efficacy of this conversion strategy in Chinese renal transplant recipients.
Methods: In this single-center study, 16 stable renal transplant recipients were observed for 1
year after a milligram to milligram switch from standard-release to prolonged-release tacroli-
mus formulation. Trough blood tacrolimus level and graft function were serially monitored.
Results: Mean daily dose of tacrolimus was 0.040  0.018 mg/kg before conversion. After
conversion, we observed a significant decrease in trough tacrolimus levels, from
4.5  2.2 ng/mL to 3.4  1.1 ng/mL (pZ 0.046) at 1 month, and from 4.5  2.2 ng/mL to
3.3 1.1 ng/mL (pZ 0.01) at 12 months. After 12 months, 44% of patients (nZ 7) experienced
a decrease in tacrolimus blood levels of more than 20%. All patients maintained stable graft
function otherwise, without acute rejection.
Conclusion: Our findings confirm that trough tacrolimus blood level can decrease following
a 1:1 (mg:mg) conversion from standard-release to prolonged-release tacrolimus formulation
in Chinese patients. Close monitoring of the drug levels and clinical condition seems to be war-
ranted after medication switch.
背景: 從標準釋放型 tacrolimus轉換至一天一次延長釋放型 tacrolimus通常是按 1:1 (mg:mg)的
比例進行；以下研究以華裔腎臟移植接受者為對象，對此轉換法的功效及安全性作出調查。lumni.cuhk.net (K.M. Chow).
g Kong Society of Nephrology Ltd. Published by Elsevier Taiwan LLC. All rights reserved.
Prolonged-release tacrolimus conversion 65方法: 本研究於單一院所進行，參與者為 16 位穩定的腎臟移植接受者，從標準釋放型轉換至延長
釋放型 tacrolimus (按 1:1之 mg:mg比例)後接受 1年的持續追蹤，內容包括 tacrolimus谷底血
液濃度及植入腎臟功能。
結果: 轉換前，tacrolimus 之平均劑量為 0.040 0.018 mg/kg；轉換後，tacrolimus 谷底濃度呈
現明顯下降：1 個月時從 4.5  2.2 ng/mL 至 3.4  1.1 ng/mL (pZ 0.046)，12 個月時從
4.5 2.2 ng/mL 至 3.3 1.1 ng/mL (pZ 0.01)。在經過 12 個月後，44% 的病人 (nZ 7) 呈現
>20% 的 tacrolimus 血液濃度降幅。然而，所有病人的植入腎臟均維持穩定的功能，未出現急性
排斥現象。
結論: 本研究證實在華裔病人間，從標準釋放型 tacrolimus 按 1:1 (mg:mg) 比例轉換至延長釋放
型 tacrolimus 後，tacrolimus 谷底濃度會有所下降，因此理應有需要在轉換後密切監察病人的
藥物濃度及臨床狀況。Introduction
Tacrolimus, an oral macrolide calcineurin inhibitor with
potent immunosuppression effect, was first marketed as
a twice-daily preparation. A newer prolonged-release
formulation of tacrolimus is now available. This modified
once-daily tacrolimus is supposed to improve patient
adherence.
Several conversion studies have reported a 1:1 (mg:mg)
conversion of standard-release tacrolimus to prolonged-
release tacrolimus in stable liver and renal transplant
recipients.1e3 Most of these data have been derived from
studies among Caucasian populations. In recent years,
pharmacogenetic studies have confirmed the influence of
various gene polymorphisms on tacrolimus dose require-
ments in Chinese.4 A substantial impact of genetic poly-
morphism on intrasubject pharmacokinetic variation to
tacrolimus has also been shown among Asians in a bio-
equivalence study.5 Furthermore, a post-marketing surveil-
lance study showed a decrease in tacrolimus exposure after
a switch from standard-release to prolonged-release tacro-
limus on a milligram per milligram basis.6 Considering that
tacrolimus is a highly variable drug and the lack of reports
on the two formulations of tacrolimus in Chinese, we carried
out an observational study to evaluate the tacrolimus
conversion strategy on a simple 1:1 mg basis in stable
Chinese renal transplant recipients.Methods
This was an open-label study to determine the safety and
efficacy of conversion from standard-release to prolonged-
release tacrolimus formulation in stable renal transplant
recipients. A selected low-risk group of transplant recipi-
ents was recruited: patients older than 18 years with
a minimum of 1 year since kidney transplantation and
stable graft function were eligible for the current study.
Selected renal transplant recipients had a 1:1 (mg:mg)
dose conversion of standard-release tacrolimus to prolonged-
release tacrolimus. They were then followed-up on a regular
basis in the outpatient clinic. Their serum creatinine levels,
tacrolimus doses, and trough tacrolimus levels were
analyzed. Glomerular filtration rate was estimated by the
abbreviated version of the Modification of Diet in Renal
Disease (MDRD) Study equation.7 Blood concentrations oftacrolimus were determined by high-performance liquid
chromatographyetandem mass spectrometry. The length of
observation after conversionwas 1 year. No surveillance graft
biopsies were performed. Indication biopsies were manda-
tory in cases of elevated serum creatinine of 15% over base-
line. Safety assessment was based on individual adverse
events, the results of routine clinical laboratory tests, and
the incidence of biopsy-proven acute rejection. Patients
underwent regular monitoring of laboratory values at 0, 1, 2,
6, 9 and 12 months.
Data are expressed in mean standard deviation unless
otherwise specified. Values between different assessments
were compared by the paired t-test and those between
patients by unpaired t-test. Two-tailed p values <0.05 were
considered statistically significant. Statistical analyses
were performed using SPSS version 16.0 (SPSS Inc., Chicago,
IL, USA).
Results
Sixteen stable Chinese renal transplant recipients were
recruited; four (25%) were male, and the mean age at the
time of drug conversion was 47.0 9.9 years. The median
duration of renal transplant was 4.5 years (range, 1e16
years). Mean body mass index of our study patients was
21.9 3.5 kg/m2. No patient was lost to follow-up.
At study entry, the total dose of standard-release
tacrolimus ranged from 1.0 mg/day to 4.0 mg/day. The
mean daily dose of tacrolimus was 2.2 1.2 mg (or
0.040 0.018 mg/kg), with a corresponding mean trough
tacrolimus level of 4.5 2.2 ng/mL. Mean prednisolone
dose was 4.8 0.6 mg/day. Seven (44%) patients were
receiving azathioprine and 6 (38%) were receiving myco-
phenolate antiproliferative agent (at a mean dose of
mycophenolate mofetil 791.7 245.8 mg/day). Three-
quarters of the patients were taking diltiazem concur-
rently, and the drug was not changed during the study
period. None of our patients were on proton-pump inhibi-
tors. After drug conversion, the trough levels of tacrolimus
at 1, 2, 6, 9 and 12 months were 3.4 1.1 ng/mL,
3.6 1.2 ng/mL, 3.8 1.7 ng/mL, 3.5 1.0 ng/mL and
3.3 1.1 ng/mL, respectively (Fig. 1). Based on clinical
judgment, it was decided to increase the total daily
tacrolimus dose in two of the 16 patients (12.5%). One
patient required an additional 1 mg (from 1.5 mg to 2.5 mg
daily) within the observation period. Another patient
Figure 1 Comparison of trough tacrolimus levels after
formulation conversion. The bar represents mean standard
deviation. *p< 0.05 versus baseline trough tacrolimus level;
**pZ 0.01 versus baseline trough tacrolimus level.
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2.5 mg daily). Overall, a significant difference in trough
tacrolimus levels was observed between baseline and 1
month (4.5 2.2 ng/mL vs. 3.4 1.1 ng/mL, pZ 0.046)
and 12 months (4.5 2.2 ng/mL vs. 3.3 1.1 ng/mL,
pZ 0.01). At the end of 12 months, 44% of patients (nZ 7)
experienced a decrease in blood levels of tacrolimus of
more than 20%.
The mean serum creatinine level before drug conversion
was 122 86 mmol/L (range, 46e395 mmol/L). Serum
creatinine levels remained stable over time; they were
124 84 mmol/L and 121 97 mmol/L at 1 and 12 months
after drug conversion, respectively. No difference in serum
creatinine levels was observed between baseline and that
measured at 1, 2, 6, 9 and 12 months. No patients experi-
enced acute rejection during the course of the study. There
was no significant difference between the estimated
glomerular filtration rate at baseline and 1 year after
tacrolimus conversion (63.1 27.9 mL/min/1.73 m2 vs.
64.0 24.2 mL/min/1.73 m2, pZ 0.67).
Discussion
In this single-center observational study, we demonstrated
a significant decrease in tacrolimus trough blood level after
a 1:1 (mg:mg) conversion from standard-release to
prolonged-release once-daily tacrolimus formulation in
stable Chinese renal transplant recipients. The current
recommendation for tacrolimus conversion from standard-
release to prolonged-release formulation is for a simple 1:1
(mg:mg) switch. Our data, on the other hand, support more
recent observations6e10 of a decrease in trough tacrolimus
levels after drug conversion, and question the reliability of
switching on a milligram per milligram basis.
A difference in the efficacy, on a milligram per milligram
basis, of the two formulations of tacrolimus was first re-
ported in de novo renal transplant recipients from Europe.Significantly higher doses of prolonged-release tacrolimus,
up to 50%, were needed to achieve a similar therapeutic
trough level as standard-release tacrolimus during the first 6
months of renal transplantation.11 Although the difference
tended to diminish with time after transplantation, a statis-
tically significant decrease in trough tacrolimus level with
a 1:1 (mg:mg) switch to prolonged-release tacrolimus was
also found among maintenance renal transplant recipi-
ents.6e10 For instance, in two large retrospective studies of
maintenance renal transplant recipients with tacrolimus
conversion (median period of transplant, 3.1e4.5 years),
38.3e47.2% of patients experienced a decrease in trough
level exceeding 20%.6,9 This finding is very similar to that
observed in our Chinese cohort, of which 44% showed
a decrease in tacrolimus blood levels of more than 20% after
tacrolimus formulation switch.
Our study has several limitations. With respect to esti-
mating tacrolimus drug exposure, we must emphasize that
we did not measure the area under the curve (AUC) before
and after drug conversion. Whether or not a lower trough
level after once-daily prolonged-release tacrolimus implies
a lower AUC is debatable. In general, trough levels for
prolonged-release tacrolimus has been considered to be the
same as for standard-release tacrolimus12; the relationship
between tacrolimus trough level and AUC was shown to be
equivalent for the two drug formulations based on studies
in de novo and maintenance renal transplant recipients.8,13
Still, controversy prevails as to whether or not trough
tacrolimus level reliably reflects the AUC between the two
tacrolimus formulations. A recent pharmacokinetic study in
patients with 1:1 tacrolimus drug conversion confirmed
a significant reduction in the trough and peak concentra-
tions (Cmax) of tacrolimus after conversion, but there was
no significant change in AUC.10 Ideally, concentration time
profiles should be performed so that a firm conclusion can
be drawn with regard to the tacrolimus AUC before and
after conversion.
The small number of cases in this study is another obvious
limitation, because it precludes meaningful assessment of
clinical events. Although none of our study patients experi-
enced acute rejection or adverse events, the clinical impact
of a decreased trough blood tacrolimus level is not easily
assessed with a sample size of only 16 stable patients. During
an unplanned extension of the follow-up period (24.4 1.9
months after drug conversion), there was no acute rejec-
tion. Of note, there have been no reports in the literature of
adverse events related to lower trough tacrolimus levels
following formulation switching.
In contrast to previously published data, we found that
conversion of standard-release tacrolimus to once-daily
prolonged-release tacrolimus on a 1:1 mg basis could result
in a lower trough blood level of tacrolimus. The clinical
consequences of this remain unknown. Our observation lends
credence to the premise that close monitoring of tacrolimus
trough levels and the patient’s clinical condition is war-
ranted after switching tacrolimus formulations.Acknowledgments
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